智通财经APP讯，百龙创园(605016.SH)发布公告，公司拟向不特定对象发行可转换公司债券，募集资 金总额为不超过7.48亿元(含本数)，募集资金在扣除相关发行费用后拟全部投资于：泰国大健康新食品 原料智慧工厂项目、功能糖干燥扩产与综合提升项目。 ...

格隆汇12月5日丨百龙创园(605016.SH)公布，本次向不特定对象发行可转换公司债券募集资金总额为不 超过人民币7.48亿元（含本数），募集资金在扣除相关发行费用后拟全部投资于以下项目：泰国大健康 新食品原料智慧工厂项目及功能糖干燥扩产与综合提升项目。 ...

来源：新浪证券-红岸工作室 12月4日，百龙创园跌2.01%，成交额4891.46万元，换手率0.57%，总市值86.10亿元。 异动分析 1、公司生产的健康甜味剂产品主要为阿洛酮糖，阿洛酮糖是在自然界中天然存在但含量极少的一种稀 有单糖，其甜味及口感与蔗糖相当类似或接近，但其热量却远低于蔗糖，对于肥胖以及糖尿病患者是一 种理想的蔗糖代替物。 2、2024年半年报，公司持有山东禹城农村商业银行股份有限公司 5.14%股份。 3、根据2024年年报，公司海外营收占比为60.62%，受益于人民币贬值。 4、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-229.84万，占比0.05%，行业排名92/181，连续2日被主力资金减仓；所属行业主力净流 入-13.76亿，连 ...

证券日报网讯 12月2日，百龙创园在互动平台回答投资者提问时表示，截至2025年11月30日，公司股东 总户数为10948户。 （文章来源：证券日报） ...

Core Points - The company held its fourth extraordinary general meeting of shareholders on December 1, 2025, with no resolutions being rejected [2][3] - The meeting was convened by the board of directors and chaired by Chairman Dou Baode, utilizing a combination of on-site and online voting methods [2][3] - A special resolution regarding the company's previous fundraising usage report was approved, requiring more than two-thirds of the voting rights held by attending shareholders [3][5] Meeting Details - The meeting took place at the company's office building in Yucheng, Dezhou, Shandong Province [2] - All seven current directors attended the meeting, along with the board secretary and other senior executives [4] - The meeting's legal compliance was confirmed by Beijing Hairun Tianrui Law Firm, ensuring that all procedures and voting were in accordance with the Company Law and relevant regulations [5][6]

证券代码：605016 证券简称：百龙创园 公告编号：2025-073 山东百龙创园生物科技股份有限公司 2025年第四次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 12 月 1 日 (二)股东会召开的地点：山东省德州市禹城市高新技术开发区德信大街百龙创园 公司办公楼一楼第二会议室 络投票相结合的方式进行表决。本次股东会的召集、召开以及表决方式符合《公 司法》、《公司章程》及相关法律、法规的规定。 (五)公司董事和董事会秘书的出席情况 1、公司在任董事7人，出席7人； (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 132 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 218,042,031 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 51.9132 | | 份总数的比例（ ...

中国·北京 北京海润天睿律师事务所 北京市朝阳区建外大街甲 14 号广播大厦 5&9&10&13&17 层 邮编:100022 电话：(010)65219696 传真：（010）88381869 2025 年第四次临时股东会的法律意见书 关于山东百龙创园生物科技股份有限公司 法律意见书 北京海润天睿律师事务所 关于山东百龙创园生物科技股份有限公司 2025 年第四次临时股东会的法律意见书 致：山东百龙创园生物科技股份有限公司 北京海润天睿律师事务所（以下简称"本所"）接受山东百龙创园生物科技 股份有限公司（以下简称"公司"）的委托，指派律师潘仙、张阳出席公司 2025 年第四次临时股东会，并依据《中华人民共和国公司法》（以下简称"《公司法》"） 等法律法规、规范性文件及《山东百龙创园生物科技股份有限公司章程》（以下 简称"《公司章程》"）的有关规定，对本次股东会相关事项依法进行见证并发 表法律意见。 为出具本法律意见书，本所律师出席了公司本次股东会，审查了公司提供的 召开本次股东会的有关文件。公司已向本所及本所律师承诺，其所提供的文件和 所作的陈述、说明是完整、真实和有效的，无任何隐瞒、遗漏，并据此出具法律 ...

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing positive market movements, with a recent stock price increase and significant revenue growth, driven by its innovative health sweetener products and strategic investments in the banking sector [1][2][4]. Company Overview - Shandong Bailong Chuangyuan Biotechnology Co., Ltd. was established on December 30, 2005, and went public on April 21, 2021. The company specializes in the research, production, and sales of prebiotic series products, dietary fiber series products, and health sweeteners [8]. - The company's main business revenue composition includes dietary fiber series (54.15%), prebiotic series (28.00%), health sweeteners (13.57%), and others (3.91%) [8]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 969 million yuan, representing a year-on-year growth of 18.10%. The net profit attributable to the parent company was 265 million yuan, with a year-on-year increase of 44.93% [8]. - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9]. Market Position and Strategic Advantages - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which positions it favorably within the financial sector [3]. - The company benefits from a 60.62% share of overseas revenue, aided by the depreciation of the Chinese yuan [4]. - It has been recognized as a "specialized, refined, characteristic, and innovative" small giant enterprise, which enhances its competitiveness and stability within the industry [4]. Stock Market Activity - The stock price of Bailong Chuangyuan increased by 2.61%, with a trading volume of 126 million yuan and a turnover rate of 1.42%, leading to a total market capitalization of 8.904 billion yuan [1]. - The stock has shown a slight net outflow of 22.4583 million yuan from major investors, indicating a lack of strong buying momentum [5][6].

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing growth in its health sweetener products, particularly allulose, which is beneficial for obesity and diabetes patients. The company is also benefiting from its stake in a rural commercial bank and the depreciation of the RMB, while being recognized as a "specialized, refined, distinctive, and innovative" enterprise [2][3][4]. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotic series products, dietary fiber series products, and health sweeteners, with revenue contributions of 54.15% from dietary fiber, 28.00% from prebiotics, and 13.57% from health sweeteners [8]. - As of October 31, the company had 13,400 shareholders, with an average of 31,274 circulating shares per person, reflecting a 3.62% decrease [8]. - The company reported a revenue of 969 million yuan for the period from January to September 2025, representing an 18.10% year-on-year growth, and a net profit of 265 million yuan, which is a 44.93% increase year-on-year [8]. Group 2: Financial Performance - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9]. - The average trading cost of the company's shares is 20.58 yuan, with the current stock price near a support level of 20.53 yuan [7]. - The company’s market capitalization is 8.677 billion yuan, with a trading volume of 40.56 million yuan and a turnover rate of 0.47% on November 27 [1]. Group 3: Market Position and Recognition - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which contributes to its financial stability [3]. - The company is recognized as a "specialized, refined, distinctive, and innovative" enterprise, which enhances its competitiveness and stability within the industry [4]. - The company’s overseas revenue accounts for 60.62% of its total revenue, benefiting from the depreciation of the RMB [4].

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., has shown significant growth in revenue and profit, benefiting from its unique product offerings and market positioning in the health sweetener sector. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotic products, dietary fiber products, starch sugar (alcohol) products, and health sweeteners, with a revenue composition of 54.15% from dietary fiber, 28.00% from prebiotics, 13.57% from health sweeteners, and 3.91% from other products [8] - As of October 31, the number of shareholders increased by 3.75% to 13,400, while the average circulating shares per person decreased by 3.62% to 31,274 shares [8] Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 969 million yuan, representing a year-on-year growth of 18.10%, and a net profit attributable to the parent company of 265 million yuan, with a year-on-year increase of 44.93% [8] - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed in the last three years [9] Group 3: Market Position and Benefits - The company produces allulose, a rare monosaccharide that serves as a low-calorie alternative to sucrose, making it ideal for individuals with obesity and diabetes [2] - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which may provide additional financial benefits [3] - The company has a significant overseas revenue share of 60.62%, benefiting from the depreciation of the RMB [4] - The company has been recognized as a "specialized, refined, characteristic, and innovative" small giant enterprise, which enhances its competitiveness and stability within the industry [4] Group 4: Stock Performance and Trading Activity - On November 24, the company's stock rose by 3.74%, with a trading volume of 91.55 million yuan and a turnover rate of 1.09%, bringing the total market capitalization to 8.497 billion yuan [1] - The average trading cost of the stock is 20.57 yuan, with recent selling pressure observed, indicating a need for potential portfolio adjustments [7]